Pepticom

Jerusalem-based Pepticom uses biocomputational AI software to design novel peptide drug candidates that speed up the drug development process while reducing risks and costs. The company claims its technology is capable of screening 1,030 possible molecular options—higher than other screening techniques—to find suitable candidates. 

Key customers and partnerships

Pepticom has several undisclosed in-house programs at the discovery stage and has also partnered with other organizations to leverage its technology in drug development such as the University of Oxford, the Hebrew University of Jerusalem, and Fraunhofer. The company has not disclosed its pharma partners. 

Funding and financials

The company raised USD 2.6 million in venture funding led by the Chartered Group in March 2021 . The proceeds were directed toward establishing PeptiCov, a spin-off company focused on the SARS-Cov-2 virus.